TZP elimination highly depends on renal function, and TZP excretion is interrupted if renal impairment occurs; therefore, TZP dosage should be adjusted according to the patient's renal function. 1, 2, 8) In South Korea, the usual TZP dose in patients with creatinine clearance (CrCl) greater than 40 mL/min is 4.5 g intravenously (IV) every 8 hours; in patients with CrCl between 20 and 40 mL/min, the TZP dose is 4.5 g IV every 8 hours; in patients with CrCl less than 20 mL/min or hemodialysis, 4.5 g TZP is administered IV every 12 hours; in febrile neutropenic patients, 4.5 g TZP is administered IV every 6 hours with aminoglycosides. 9) However, different renal function dependent doses of TZP are given in the USA and Canada. Specifically, the typical TZP dose in patients with CrCl greater than 40 mL/ min is 3.375 g or 4.5 g IV every 6 hours depending on indications. 1) In patients with CrCl between 20 and 40 mL/min, 2.25 g TZP is administered IV every 6 hours, and in patient with CrCl less than 20 mL/min, 2.25 g TZP is given IV every 8 hours.
1) For patients on hemodialysis, 2.25 g TZP is administered
IV every 12 hours.
1)
The half-life of TZP is approximately 0.7-1.2 hours in patients with normal renal function; however, its half-life increases nearly two to four times in patients with CrCl less than 20 mL/min. 1, 2) Thus, it is necessary to measure accurate renal functions before TZP is administered in order to minimize TZP-induced adverse events, as well as to optimize TZP dosing. According to a study by Karino et al. in Japan, cautious TZP administration and monitoring was necessary in elderly patients with kidney dysfunction, particularly those with CrCl less than 40 mL/min owing to serious nephrotoxicity (although TZP is effective against hospital-acquired pneumonia).
10)
Functional renal mass can be measured through the glomerular filtration rate (GFR) calculated from inulin injections, but this method is clinically impractical due to the time required for IV infusion and urine collection; hence, the Cockcroft-Gault (CG) equation is typically utilized to measure renal function.
11) The pharmaceutical industry also uses the CG equation to determine renal dosage adjustments for different drugs. [12] [13] [14] However, the use of serum creatinine concentration (SCr) as a predictive factor of kidney function in the CG equation is limited because various factors affect SCr, including age, sex, weight, and muscle mass. 11) Specifically, SCr is linked to muscle mass, and its increase is proportionally associated with lean body weight (LBW), as opposed to total body weight (TBW). 15, 16) 
19)
Few studies have been conducted regarding the efficacy and safety of TZP use in patients with cancer. 25, 26) However, the studies regarding appropriate TZP dosing based on renal function in patients with obesity and cancer have rarely been implemented. The objective of this study was to determine the appropriate administration dose of TZP according to the renal function of patients with obesity and cancer in a tertiary hospital.
METHODS

Study Population
Ethical approval for this study was granted by the Institutional Review Board of Chonnam National University Hwasun Hospital (CNUHH-2014-127). This study was conducted retrospectively with patients with obesity and cancer that had received TZP while hospitalized in the same hospital in South Korea between September 2004 and August 2014.
Among patients with cancer 18 years of age or older who had undergone TZP treatment for over 72 consecutive hours, those with BMI ≥ 30 kg/m 2 were included in this study, (BMI cutoff based on a review of the literature). 3, 17, [27] [28] [29] [30] [31] If patients were re-admitted and TZP was re-administered during the study period, they were included in the study as long as they were under TZP treatment for different afflictions within that same year, or TZP was administered in a different year.
32)
However, the following exclusion criteria were applied: patients younger than 18 years old, patients without records of height or weight essential for calculating the BMI, patients with BMI < 30 kg/m 2 , patients without information regarding diagnosis and TZP administration (e.g., indication, dosage, and duration of treatment), patients without lab value information, patients who underwent TZP treatment for less than 72 hours, patients who received TZP again due to the same affliction in the same year, or patients allergic to penicillins, cephalosporins, or beta-lactamase inhibitors. 
Data Collection
By using electronic medical records, the following information was collected: demographics, data regarding TZP administration (e.g., indication, dosage, duration of treatment, and initial purpose of TZP use), results from bacterial identification, reasons for TZP discontinuation, antibiotics and antifungals concomitantly administered, medications that could cause drug-drug interactions with TZP, type of dialysis (if patients were under it), SCr levels just before TZP administration (in cases of TZP dose changes), and clinical and hematological values (e.g. temperature, potassium, SCr, CrCl, white blood cell, red blood cell, hemoglobin, platelet, and C-reactive protein counts) before and during TZP administration (defined as within 24 to 72 hours after TZP was initially given). 4, 26, [31] [32] [33] 
Outcome Measures
To evaluate appropriate TZP dosing according to kidney function of obese patients with cancer, kidney function was classified into four stages by CrCl (CrCl > 40 mL/min, 20 mL/ min ≤ CrCl ≤ 40 mL/min, CrCl < 20 mL/min, and hemodialysis) after a thorough literature review. The appropriate TZP dose (one dose and total daily dose) on the 1st day of treatment, and the 2nd or 3rd day of treatment was evaluated based on the recommended TZP dose in Korea and other countries.
1,2,9) In case of hemodialysis patients, only the appropriate TZP dose on the 1st day of treatment was assessed since TZP dose was determined by whether or not patients were under hemodialysis.
1,2,9)
Statistical Analyses SPSS 20.0 for Windows (Chicago, IL, USA) was used to analyze data. Continuous variables are presented as mean±SD, and categorical variables are presented as frequencies (n) and percentages (%). Chi-square test or Fisher's exact test was performed to examine the differences in proportions, and a oneway ANOVA was performed to compare means between groups. The level of statistical significance was set at p<0.05.
RESULT
Demographics
A total of 7,058 patients had taken TZP during the study period; 102 TZP prescriptions met the inclusion and exclusion criteria and were selected for the analysis (Fig. 1) . Table 1 summarizes the study patients' characteristics. Thirty-eight (37.3%) prescriptions were for males, and 64 (62.7%) prescriptions were for females. The mean age of patients was 56.2 ± 16.2 years. The mean SCr before TZP administration was 1.3 ± 1.2 mg/dL. The mean BMI of the patients was 31.6 Appropriate initial dose of TZP based on renal functions prescriptions, respectively. When CrCl > 40 mL/min, almost all of prescriptions used 4.5 g TZP, which is appropriate for an initial dose (2.25 g TZP was used in two instances). When CrCl was between 20-40 mL/min, 4.5 g TZP was written as an initial dose more often than 2.25 g TZP, and when CrCl was less than 20 mL/min, 2.25 g TZP was used as the initial dose more often than 4.5 g TZP. For hemodialysis, only 2.25 g TZP was prescribed. Table 4 shows the appropriate initial total daily dose of TZP based on various body size descriptor equations. Among 102 prescriptions, 13.5 g TZP was administered as an initial total daily dose in 81 prescriptions. When CrCl > 40 mL/min, 18 g TZP was used in one prescription, and there was one prescription where 6.75 g or 9 g TZP was administered against the recommended TZP dose. In the case of CrCl levels between 20-40 mL/min, 13.5 g was administered more often than 9 g TZP; however, there were two instances where 6.75 g TZP was inconsistent with the recommended TZP dose. When CrCl < 20 mL/min, 13.5 g TZP was used in one prescription, inconsistent with the recommended TZP dose. For the hemodialysis group, 9 g TZP was consistent with the recommended Korean TZP dose as written for one prescription, and 4.5 g and 6.75 g TZP were consistent with non-Korean recommended TZP doses in one and four prescriptions, respectively. An initial total daily dose of 18 g TZP was not prescribed in patients with CrCl of 20-40 mL/min; neither 13.5 g nor 18 g TZP as an initial total daily dose was administered in patients with hemodialysis. Appropriate TZP dose during the treatment based on renal functions
Evaluation of CrCl values based with various weight adjustment equations
The appropriate single dose and total daily dose of TZP during treatment was analyzed according to renal function. In this study, "during treatment" was defined as the 2nd or 3rd day of TZP administration. There were 23 patients with no measured SCr or under hemodialysis. Thus, 79 prescriptions were used to evaluate the appropriate single dose and total daily dose of TZP during treatment based on renal functions. Table 5 presents the appropriate TZP doses under treatment based on various body size descriptor equations. Out of 79 prescriptions, 2.25 g and 4.5 g TZP was used for a single dose under treatment in 14 and 65 prescriptions, respectively. When CrCl > 40 mL/min, almost all patients received 4.5 g TZP as a single dose under treatment in accordance with Korean and non-Korean recommended TZP doses; however, 2.25 g TZP was inconsistent with the recommended TZP dose in two instances. In case of CrCl levels between 20-40 mL/min, there were more prescriptions where 4.5 g TZP was administered based on the Korean recommended TZP dosage, but when CrCl < 20 mL/min, 2.25 g TZP was administered in accordance with non-Korean recommended TZP doses. Table 6 summarizes the appropriate total daily dose of TZP under treatment based on various body size descriptor equations. In 64 out of 79 prescriptions 13.5 g TZP was used. For CrCl > 40 mL/min, 18 g TZP was used in one instance, and 6.75 g and 9 g TZP (inappropriate for a patient with CrCl > 40 mL/min) were used in one instance each. TZP 13.5 g (appropriate for patients with CrCl levels between 20-40 mL/min) was administered more often than 9 g TZP. For one patient with a CrCl level between 20-40 mL/min, 6.75 g TZP was inappropriately used. For CrCl < 20 mL/min, 6.75 g or 9 g TZP was prescribed in accordance with Korean and non-Korean recommended TZP doses. A total daily dose 18 g TZP was not prescribed for patients with CrCl of 20-40 mL/min, nor was a total daily dose of 13.5 g or 18 g TZP administered in patients with CrCl < 20 mL/min.
DISCUSSION
In general, obesity-related pharmacokinetic parameters, such as volume of distribution and increase in clearance rate, may change such that a higher than average dose is necessary for effective TZP administration. 3, 29) Furthermore, patients with obesity show degraded kidney function, which means that appropriate TZP doses based on the renal function of these patients is essential in order to improve the quality of medical treatment and minimize side effects. 8) To our knowledge, studies on appropriate TZP doses for obese patients with cancer have been rare in Korea, which lends further meaning to our study that analyzes this specific patient group. Contrary to previous studies, our study used appropriate equations to adjust the weight of obese patients. 2, 11, 15, [19] [20] [21] The adjusted weights of the patients were calculated using IBW, LBW (1976), and LBW (2005), and the CrCl levels calculated with CG , respectively). It is important to measure exact renal function in patients with obesity in order to adjust the doses of medications eliminated through the kidneys, including TZP. According to a study targeted toward extremely obese patients (BMI ≥ 40 kg/ m 2 ), the CrCl levels acquired by substituting LBW (2005) into the CG equation corrected the difference between estimated and actual renal function. 19) However, since the subjects included in the aforementioned study were restricted to extremely obese patients, the application to other patient groups may be limited. Also, in a study published in 2012 showed that calculating CrCl levels with various weight adjustment equations according to BMI values may reduce the difference between estimated and actual CrCl levels.
20)
Therefore, it is necessary to perform a prospective clinical study to determine the exact weight adjustment equation through comparison of measured CrCl levels with estimated CrCl levels by using various weight adjustment equations. TZP dosage varied depending on renal function and indications, but in general, 3.375 g and 4.5 g TZP were administered IV over 30 minutes every 6 and 6-8 hours, respectively. 1,2) However, TZP dosage in Korea is different than that used in America and Europe. 1,2,9) Specifically, when CrCl > 40 mL/min, there was no difference between Korean and non-Korean recommended total daily doses of TZP for all indications, except empirical treatments for patients with febrile neutropenia. 2,9) To cure patients with febrile neutropenia, 13.5 g TZP per day was recommended in other countries, but 18 g TZP per day was suggested in Korea. In addition, the difference in recommended daily doses of TZP was significant when patient renal function was degraded; for most indications (except nosocomial pneumonia), the recommended daily dose of TZP in Korea was relatively higher than recommendations from other countries. 
33)
Based on the initial TZP dose analysis, for CrCl levels > 40 mL/ min, 4.5 g TZP was used in all prescriptions (excluding two prescriptions). We found that an appropriate initial TZP dose was administered to most of the patients. For CrCl levels between 20-40 mL/min, an initial dose of 4.5 g TZP is recommended in Korea and 2.25 g TZP in other countries; therefore, if an initial TZP dose were administered to patients based on a Korean recommendation, patients in Korea would receive twice the recommended dose than patients in other countries.
1,2,9)
According to the initial TZP dose analysis in this group, twice the number of patients was injected with 4.5 g TZP for an initial dose, not 2.25 g TZP. However, this study did not evaluate how TZP dose differences affect the treatment of patients with degraded kidney functions. This point should be addressed in future studies.
Our study has some limitations that should be addressed. This study was conducted retrospectively through electronic patients' medical records, and the appropriate TZP dosing under treatment was determined based on whether or not SCr existed on the 2nd or 3rd day after the initiation of TZP; this could affect assessment of the appropriate TZP dosing under treatment. In this study, the obesity of patients with cancer under TZP during the study period was determined based on the obesity criteria from the World Health Organization. However, these criteria are different from the Korean Society for the Study of Obesity criteria, such that the results from this study may differ from the patient's original obesity rates. Lastly, when SCr values were less than 1 mg/dL in patients aged ≥ 65 years, those were rounded to 1 mg/dL. However, it was found that if CrCl values
